Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ConvaTec","sponsor":"30 Technology","pharmaFlowCategory":"D","amount":"$218.0 million","upfrontCash":"$55.9 million","newsHeadline":"30 Technology's Clinically Validated Antimicrobial Nitric Oxide Platform Acquired by Convatec Group Plc for Several Applications","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by ConvaTec

    Menu

    ConvaTec

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ConvaTec

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              30 Technology's Clinically Validated Antimicrobial Nitric Oxide Platform Acquired by Convatec Group Plc for Several Applications

              Details:

              The divestment will allow 30 Technology to accelerate its ultra-broad spectrum NO-generation and rapidly advance its innovative and differentiated platform of NO-generating technologies, including RESP301, a NO-generating liquid designed to release NO in situ.

              Lead Product(s): RESP301

              Therapeutic Area: Genetic Disease Product Name: RESP301

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: 30 Technology

              Deal Size: $218.0 million Upfront Cash: $55.9 million

              Deal Type: Divestment April 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY